Curated News
By: NewsRamp Editorial Staff
July 21, 2026

VivoSim Labs Raises $4M for Innovative 3D Tissue Testing

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • VivoSim raised $4M at $0.85 per share, offering investors a low entry point with potential upside from FDA policy shifts.
  • VivoSim issued 4.7M shares and warrants at $0.85 each, with proceeds for working capital and shareholder approval needed for warrant amendments.
  • VivoSim's 3D tissue models could reduce animal testing, advancing ethical drug development and improving human health outcomes.
  • The company amended existing warrants from $9.60 to $0.85, dramatically lowering the exercise price for early investors.

Impact - Why it Matters

This news matters because VivoSim Labs is pioneering non-animal testing methods using 3D human tissue models, which could significantly reduce drug development costs and ethical concerns. The $4 million raise will fuel their growth and accelerate adoption of these advanced methodologies, potentially leading to safer and more effective drugs. For investors, the amended warrant terms signal confidence in the company's trajectory, while the broader biotech industry may see a shift toward regulatory acceptance of NAM technologies.

Summary

VivoSim Labs, Inc. (NASDAQ: VIVS) has announced a significant capital raise of approximately $4 million through a private placement with a single healthcare-focused institutional investor. The company will issue 4,705,883 shares of common stock (or equivalents) and accompanying warrants at a combined price of $0.85 per share. The warrants, exercisable after shareholder approval, have a five-year term and an exercise price of $0.85. Additionally, VivoSim has agreed to amend certain existing May 2024 warrants, reducing their exercise price from $9.60 to $0.85 per share, subject to shareholder approval. The offering is expected to close around July 17, 2026, pending customary conditions. Net proceeds will be used for working capital and general corporate purposes.

VivoSim Labs is a pharmaceutical and biotechnology services company specializing in testing drugs and drug candidates using three-dimensional (3D) human tissue models of the liver and intestine. Their innovative new approach methodologies (NAM) provide toxicology insights, potentially reducing reliance on animal testing. The company anticipates accelerated adoption of human tissue models following the FDA’s Roadmap to refine animal testing requirements in favor of non-animal NAM methods. Headquartered in San Diego, CA, VivoSim aims to transform drug safety testing.

The press release was distributed by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. MissionIR provides syndicated content, press release enhancement, and social media distribution to help companies gain visibility among investors. For more details, the full press release is available at https://ibn.fm/7Ov0B.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VivoSim Labs Raises $4M for Innovative 3D Tissue Testing

blockchain registration record for this content.